基于真实世界的数据对塞马格卢提德安全性的评估:从流行到自发报告在EudraVigilance数据库中的流行
Anca Butuca1, Carmen Maximiliana Dobrea1, Anca Maria Arseniu1
1Preclinical Department, Faculty of Medicine, "Lucian Blaga" University of Sibiu, 2A Lucian Blaga St., 550169 Sibiu, Romania.
Biomedicines
|May 25, 2024
概括
作为GLP-1RA的塞马格卢提德 (SEM) 显示了公众对减肥的高度兴趣,但也经常出现过量报告. 仔细监测非标签使用对于尽量减少药物不良反应至关重要.
科学领域:
- 药物监督 药物监督 药物监督
- 使用药物使用药物.
- 数字流行病学数字流行病学
背景情况:
- 葡萄糖类-1受体激动剂 (GLP-1RA) 已被批准用于治疗2型糖尿病 (T2DM) 和肥胖症.
- 社交媒体影响了GLP-1RA的非标签使用,特别是体重管理的赛马格卢提德 (SEM).
- 越来越多的兴趣需要了解公众对这些药物的看法和安全概况.
研究的目的:
- 通过谷歌搜索数据评估公众对减肥的西马格卢提德 (SEM) 的兴趣.
- 通过EudraVigilance (EV) 数据调查与SEM相关的药物不良反应 (ADR).
- 将SEM的安全性和利用模式与其他GLP-1受体激动剂进行比较.
主要方法:
- 对SEM的谷歌搜索查询进行分析,重点关注"减肥"术语.
- 在SEM的EudraVigilance (EV) 中对个案安全报告 (ICSR) 的描述性和不成比例分析.
- 对SEM数据与其他GLP-1RA进行比较分析.
主要成果:
- 与"减肥"相关的谷歌搜索中,SEM的比例最高.
- 在SEM中,严重ADR的数量最低,但在EV中报告的ICSR的数量最高,包括过量报告的高趋势.
- 最常使用的非标签类药物是塞马格卢提德 (SEM) 和提泽帕提德 (TIR).
结论:
- 塞马格卢提德 (SEM) 显示出大量公众对减肥的兴趣,但由于非标签使用和过量服用的报告,需要仔细监测.
- 建议减少和密切监测GLP-1RA的非标签使用,如SEM,以减轻ADR风险.
- 对于SEM,没有出现意外的安全问题,但需要保持警.
关键词:
欧德拉 警 监控 监控 监控这就是GLP-1.肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖在标签之外使用.过量服用过量服用过量塞马格卢提德 (semaglutide) 是一种可怕的药物.剂量不足的情况.减肥 减肥 减肥 减肥 减肥 减肥更多相关视频
10:17High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
9.6K
06:19Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
794
相关概念视频
Pharmacovigilance
825
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
825
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Antiepileptic Drugs: Potassium Channel Activators
173
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
173
